Ensoma
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
451 D St Ste 600, Boston, Massachusetts,...Website
www.ensoma.comRevenue
$25.8 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
3
2
1
1
1
1
About Ensoma
Ensoma is a biotechnology company pioneering in vivo gene editing therapies that reprogram hematopoietic stem cells directly inside the body to treat a range of genetic diseases with a single, curative dose.Explore more
Ensoma Org Chart
Get the full picture
Sign in to uncover key details.
Show More
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Ensoma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Ensoma
Product Launch: Get notified when Ensoma launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Ensoma had a recent Job posting/layoffs
Ensoma, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Ensoma has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Ensoma has new funding data
Check out if Ensoma is spiking on competitors!
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Ensoma recently announced quarterly report
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Ensoma
Compare insights from companies similar to Ensoma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Ensoma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Ensoma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Ensoma.
Ensoma financials insights
Gather financial insights about Ensoma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Series A
$70M
2023
Series B
$135M
2025
Other Financing Round
$53M
Ensoma Tech Stack
A closer look at the technologies used by Ensoma
Most Recent Scoops
Funding
Funding
Person-Based
New Hire
Executive Move
Executive Moves, New Hire
Event
Events, Medical Research, Pharmaceuticals, Clinical Operations, Healthcare Operations, Healthcare Technology
New Hire
Executive Move
Executive Moves, New Hire
Ensoma News & Media
Ensoma Announces FDA Clearance of IND Application for First In Vivo HSC-Directed Gene Insertion Therapy
BOSTON--(BUSINESS WIRE)--Ensoma, a genomic medicines company advancing the future of medicine through one-time, in vivo therapies, today announced U.S. Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) application for its lead program EN-374 in X-linked chronic granulomatous disease (X-CGD), a rare and severe genetic disorder. EN-374 is a first-in-class in vivo hematopoietic stem cell (HSC)-directed therapy for X-CGD, which is caused by mutations in the CYBB genEnsoma to Present Preclinical Data and Manufacturing Advancements for In Vivo HSC Engineering Platform to Treat Cancer, Immune Disorders and Genetic Diseases at ASGCT 28th Annual Meeting
BOSTON--(BUSINESS WIRE)--Ensoma will present preclinical data and manufacturing advancements at the ASGCT 28th Annual Meeting, hosted May 13-17 in New Orleans.Ensoma Receives Rare Pediatric Disease and Orphan Drug Designations for EN-374 for Treatment of Chronic Granulomatous Disease
BOSTON--(BUSINESS WIRE)--Ensoma has received rare pediatric disease and orphan drug designations from the FDA for EN-374 for the treatment of X-CGD.Ensoma Unveils Three Programs Leveraging In Vivo Hematopoietic Stem Cell Engineering Platform to Target Genetic, Immune and Oncological Diseases
BOSTON--(BUSINESS WIRE)--Ensoma has unveiled its three lead programs in chronic granulomatous disease (CGD), sickle cell disease (SCD) and solid tumors.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Ensoma
Sign Up For FreeTo access detailed company insights
Ensoma is a biotechnology company pioneering in vivo gene editing therapies that reprogram hematopoietic stem cells directly inside the body to treat a range of genetic diseases with a single, curative dose.... Read More
